Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Starbloom Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences Investors Increase Investment in LIfT and Johnson and Johnson Welcomes LIfT into JLABS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Minaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT BioSciences Announces Breakthrough Preclinical Data Demonstrating the Dual Mode of Action Commonly Believed Necessary for Curing Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT Biosciences Announces Data Demonstrating Potent Killing of Pancreatic Cancer Tumouroids","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences Gets UK Grant For IMAN Cell Therapy Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by LIfT Biosciences

    Menu

    LIfT Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              LIfT Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIfT BioSciences Gets UK Grant For IMAN Cell Therapy Development

              Details:

              The grant will enable LIfT to show how its immunomodulatory alpha neutrophils recruit immune cells in vivo to attack tumours using a new type of translational humanised mouse model.

              Lead Product(s): Neutrophil-based Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Innovate UK

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding May 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LIfT Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIfT Biosciences Announces Data Demonstrating Potent Killing of Pancreatic Cancer Tumouroids

              Details:

              An Immunomodulatory Alpha Neutrophil (IMAN) exhibits a dual mode of action that enables them to be both exceptional cytotoxic directly and immunomodulatory to recruit the rest of the immune system also to destroy solid tumours like pancreatic cancer tumouroids.

              Lead Product(s): Alpha Neutrophil-based Therapy

              Therapeutic Area: Oncology Product Name: Undiclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LIfT Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIfT BioSciences Announces Breakthrough Preclinical Data Demonstrating the Dual Mode of Action Commonly Believed Necessary for Curing Solid Tumours

              Details:

              Pre-clinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities, as it stimulated CD4, CD8, NK cells increasing tumour cell death.

              Lead Product(s): Immunomodulatory Alpha Neutrophil

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LIfT Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership

              Details:

              The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.

              Lead Product(s): Neutrophil Progenitor-based Leukocyte Infusion Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Minaris

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LIfT Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIfT BioSciences Investors Increase Investment in LIfT and Johnson and Johnson Welcomes LIfT into JLABS

              Details:

              N-LIfT (neutrophil only leukocyte infusion therapy) works by effectively transferring the innate immunity that some exceptional people naturally have in their body from their stem cells to cancer patients.

              Lead Product(s): Neutrophil based Leukocyte Therapy

              Therapeutic Area: Oncology Product Name: N-LIfT

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Starbloom Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing December 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY